Highlights 180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Delayed Nasdaq Other stock markets 16:20:14 15/05/2024 BST			5-day change	1st Jan Change
1.96 ^USD	-2.00%		-1.51%	-51.68%

05-09	180 Life Sciences Corp. Announces Management Changes	CI
05-09	180 Life Sciences Corp. Announces Chief Executive Officer Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
180 Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency	18/10/23	CI
180 Life Sciences Corp. and Oxford University Innovation Limited Enter into a Termination Letter, Formally Terminate the License	28/09/23	CI
180 Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/08/23	CI
180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake	07/08/23	CI
180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment	03/08/23	CI
180 Life Sciences Corp. Announces the Filing of A Provisional Patent Describing the Combination of CBD with GLP-1 Agonists to Suppress Appetite	31/07/23	CI
180 Life Sciences Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
180 Life Sciences Announces Allowance of Claims for A US Patent for Dupuytren's Disease Treatment and Application	23/02/23	CI
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial	22/02/23	CI
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)	10/01/23	BU
180 Life Sciences Provides Update on Progress to Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture	30/11/22	CI
NOTE 2 - GOING CONCERN AND MANAGEMENT'S PLANS	10/11/22	AQ
180 Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
NOTE 2 - GOING CONCERN AND MANAGEMENT'S PLANS	09/08/22	AQ
180 Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
180 Life Sciences Says UK Medicines Regulator Requires More Data to Support Phase 2b Study of Dupuytren's Treatment Candidate	15/06/22	MT
180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease	14/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Highlights

Filters